It remains in Phase 3 clinical trials with regulatory submissions expected after trials complete in 2026 and potential approval in 2027
Both combine GHK-Cu, BPC-157, and TB-500
They are often used as second-line therapy, particularly in older adults or those at risk of hypoglycaemia
[7] [8] GLP-1 plays a crucial role in glucose homeostasis by stimulating insulin secretion in a glucose-dependent manner, suppressing glucagon release, slowing gastric emptying, and promoting satiety through central nervous system pathways
Tirzepatide is administered through a once-weekly subcutaneous injection in the abdomen, thigh, or upper arm
*Correspondence: Beatriz Rodrguez Jimnez, [email protected] Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers